GLYSET SUMMARY
Glyset® miglitol tablets
GLYSET Tablets contain miglitol, an oral alpha-glucosidase inhibitor for use in the management of non-insulin-dependent diabetes mellitus (NIDDM).
GLYSET Tablets, as monotherapy, are indicated as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone. GLYSET may also be used in combination with a sulfonylurea when diet plus either GLYSET or a sulfonylurea alone do not result in adequate glycemic control. The effect of GLYSET to enhance glycemic control is additive to that of sulfonylureas when used in combination, presumably because its mechanism of action is different.
In initiating treatment for NIDDM, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling blood glucose and symptoms of hyperglycemia. The importance of regular physical activity when appropriate should also be stressed. If this treatment program fails to result in adequate glycemic control, the use of GLYSET should be considered. The use of GLYSET must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.
|
NEWS HIGHLIGHTS
Published Studies Related to Glyset (Miglitol)
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. [2008.09]
Visceral obesity and insulin resistance are regarded as risk factors for atherosclerosis. Epidemiologic studies have demonstrated long-term anti-atherosclerotic effects with administration of alpha-glucosidase inhibitors.
Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus. [2007.06]
Postprandial hyperglycaemia and spikes have deleterious effects on Insulin secretion and sensitivity. The present study was undertaken to evaluate the efficacy, safety and tolerability of miglitol 50 mg three times daily for 12 weeks in 129 patients with type 2 diabetes mellitus, inadequately managed with diet and exercise therapy alone for 3 months after obtaining their written informed consent...
Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. [2007]
We recently demonstrated that administration of miglitol at 15 min after the start of a meal decreased the area under the curve (AUC) of plasma glucose, similar to the observation following its administration just before a meal. This finding prompted us to examine whether a divided-dose regimen of miglitol might attenuate postprandial glucose excursions even more effectively...
The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading. [2009.07]
Postprandial hyperglycaemia is thought to increase inflammation in leucocytes. In the present study, we examined whether sucrose loading in rats with moderate postprandial hyperglycaemia induces the expression of cytokines in peripheral leucocytes and whether these inductions are suppressed by inhibiting postprandial hyperglycaemia with the alpha-glucosidase inhibitor miglitol...
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. [2009.06]
OBJECTIVE: Postprandial hyperglycemia is thought to cause inflammation in many tissues. In this study, we examined whether the gene expression of inflammatory cytokines/cytokine-like factors in peripheral leukocytes are altered by feeding streptozotocin-treated rats a diet containing an alpha-glucosidase inhibitor, miglitol... CONCLUSION: These results suggest that miglitol inhibits the gene expression of inflammatory cytokines/cytokine-like factors in peripheral leukocytes by suppressing glucose fluctuations.
Clinical Trials Related to Glyset (Miglitol)
Double-Blind Study of Miglitol in Japanese With type2 Diabetes [Completed]
To investigate the efficacy and safety of miglitol in Japanese patients with type 2 diabetes
that is insufficiently controlled diet alone.
Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment [Completed]
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in
patients with Type1 Diabetes Mellitus treated with insulin.
Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide [Active, not recruiting]
The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in
patients with Type2 Diabetes Mellitus treated with Biguanide.
Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin [Completed]
In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2
diabetic patients treated with insulin.
Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment [Completed]
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in
patients with Type2 Diabetes Mellitus with treated insulin.
|
